IGC Pharma
6 hedge funds and large institutions have $104K invested in IGC Pharma in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
53% more capital invested
Capital invested by funds: $68K → $104K (+$36K)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.62K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$3.81K |
| 3 |
GI
Gradient Investments
Arden Hills,
Minnesota
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $43K | +$14K | +44,246 | +94% |
|
|
PAM
2
Panagora Asset Management
Boston,
Massachusetts
| $23K | – | – | – |
|
3
Creative Planning
Overland Park,
Kansas
| $21K | – | – | – |
|
|
VKH
4
Virtu KCG Holdings
New York
| $14K | -$3.81K | -12,030 | -29% |
|
|
5
UBS Group
Zurich,
Switzerland
| $2K | -$9.62K | -30,416 | -89% |
|
|
LTFS
6
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
GI
7
Gradient Investments
Arden Hills,
Minnesota
| – | -$1K | -2,000 | Closed |
|
IGC Hedge Fund Activity: Q1 2017 in Review
6 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2017, worth a combined $104K — up 53% from $68K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of IGC and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $14K. The largest seller was UBS Group, cutting an estimated $9.62K.
- 6 institutional investors held IGC Pharma (IGC) as of Q1 2017, down from 7 in Q4 2016.
- Funds reported $104K of IGC Pharma stock for Q1 2017, up 53% quarter-over-quarter.
- 0 funds opened new IGC Pharma positions in Q1 2017 and 1 closed out, a net change of -1 holder.
- The largest IGC Pharma buyer in Q1 2017 was Citadel Advisors, an estimated $14K added.
- The largest IGC Pharma seller in Q1 2017 was UBS Group, an estimated $9.62K sold.
Based on aggregated 13F filings for Q1 2017.